Atsushi Yamanaka

Dr. Atsushi Yamanaka

Miyazaki prefectural Miyazaki Hospital

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
TKTakeshi Kawaguchi
Takeshi Kawaguchi
KUKunihiko Umekita
Kunihiko Umekita
AYAtsushi Yamanaka
Atsushi Yamanaka
SHSeiichiro Hara
Seiichiro Hara
TYTetsuro Yamaguchi
Tetsuro Yamaguchi
AOAkihiko Okayama
Akihiko Okayama
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever in China, Korea, and Japan. To date, no standardized treatment protocol for SFTS has been established. Corticosteroids (CS) may be administered to patients with SFTS and hemophagocytic syndrome, but its effectiveness and safety are still debatable. We conducted a retrospective case series review at four medical facilities in Miyazaki, Japan. Based on the medical records, clinical data, including the patients background, symptoms, physical findings, laboratory data at initial presentation, treatment, and outcome, were compared between the CS-treated and the non-CS-treated group. A total of 47 patients with confirmed SFTS in each hospital were enrolled in this study; there were 14 fatal cases and 33 nonfatal cases. The case fatality ratio was 29.8%. After adjusting patients’ background by propensity score matching, the case fatality ratio was higher (p = 0.04) and complications of secondary infections, including invasive pulmonary aspergillosis, tended to be more frequent (p = 0.07) in the CS-treated group than in the non-CS-treated group. These data suggested that administration of CS to patients with SFTS should be carefully considered.

2 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
YKYumi Kirino
Yumi Kirino
KIKeita Ishijima
Keita Ishijima
MMMiho Miura
Miho Miura
TNTaro Nomachi
Taro Nomachi
MEMazimpaka Eugene
Mazimpaka Eugene
TOTamaki Okabayashi
Tamaki Okabayashi
Severe fever with thrombocytopenia syndrome virus (SFTSV) is the causative agent of SFTS, an emerging tick-borne disease in East Asia, and is maintained in enzootic cycles involving ticks and a range of wild animal hosts. Direct transmission of SFTSV from cats and dogs to humans has been identified in Japan, suggesting that veterinarians and veterinary nurses involved in small-animal practice are at occupational risk of SFTSV infection. To characterize this risk, we performed a sero-epidemiological survey in small-animal-practice workers and healthy blood donors in Miyazaki prefecture, which is the prefecture with the highest per capita number of recorded cases of SFTS in Japan. Three small-animal-practice workers were identified as seropositive by ELISA, but one had a negative neutralization-test result and so was finally determined to be seronegative, giving a seropositive rate of 2.2% (2 of 90), which was significantly higher than that in healthy blood donors (0%, 0 of 1000; p < 0.05). The seroprevalence identified here in small-animal-practice workers was slightly higher than that previously reported in other high-risk workers engaged in agriculture and forestry in Japan. Thus, enhancement of small-animal-practice workers’ awareness of biosafety at animal hospitals is necessary for control of SFTSV.

23 February 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYumi Kirino
Yumi Kirino
AYAtsushi Yamanaka
Atsushi Yamanaka
KIKeita Ishijima
Keita Ishijima
KTKango Tatemoto
Kango Tatemoto
KMKen Maeda
Ken Maeda
TOTamaki Okabayashi
Tamaki Okabayashi

12 August 2019 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
PDF file
DHDaisuke Himeji
Daisuke Himeji
GTGen-Ichi Tanaka
Gen-Ichi Tanaka
CFChikara Fukuyama
Chikara Fukuyama
AYAtsushi Yamanaka
Atsushi Yamanaka
RSRitsuya Shiiba
Ritsuya Shiiba
KMKousuke Marutsuka
Kousuke Marutsuka
A 70-year-old woman diagnosed with advanced, non-resectable programmed cell death ligand 1-positive-non-small-cell lung carcinoma was treated with pembrolizumab as first-line therapy. Soon after therapy initiation, she presented with severe dyspnea, and chest computed tomography revealed a soft tissue mass in the lower trachea of the right main bronchus. During bronchoscopy, she became severely hypoxic, and we performed endoscopic tumor ablation and Dumon Y-stent placement. We considered this severe deterioration caused by pseudoprogression, and suggest that it is necessary to perform bronchoscopy and to prepare for the bronchial intervention when treating patients with immune checkpoint inhibitors.